UroGen Pharma Dividendi e riacquisti
Criteri Dividendo verificati 0/6
UroGen Pharma non ha registrato alcun pagamento di dividendi.
Informazioni chiave
n/a
Rendimento del dividendo
-2.1%
Rendimento del riacquisto
| Rendimento totale per gli azionisti | -2.1% |
| Rendimento futuro dei dividendi | 0% |
| Crescita dei dividendi | n/a |
| Prossima data di pagamento dei dividendi | n/a |
| Data di stacco del dividendo | n/a |
| Dividendo per azione | n/a |
| Rapporto di remunerazione | n/a |
Aggiornamenti recenti su dividendi e riacquisti
Nessun aggiornamento
Recent updates
Aggiornamento narrativa • Sep 10
URGN: Patent Duration And Bladder Cancer Franchise Will Guide Balanced Future Outcomes
Analysts recently raised their fair value estimate for UroGen Pharma from $40 to $48, citing higher projected profitability, a slightly lower future P/E assumption, and stronger expectations for Zusduri product sales as the main factors behind the new price target. Analyst Commentary on UroGen Pharma Recent Street research on UroGen Pharma shows a cluster of higher fair value and price targets linked closely to expectations for Zusduri.Seeking Alpha • Sep 09
Urogen Pharma: Upside After Bladder Cancer Launch
Summary UroGen Pharma Ltd. has transitioned into a commercial-stage biopharma, driven by strong adoption of Zusduri for recurrent non-muscle invasive bladder cancer. Zusduri achieved an 80% complete response rate in the ENVISION trial, with a 64.5% chance of remaining disease-free at 3 years among responders. URGN-103, a next-generation mitomycin-based product, is positioned to replace Zusduri, offering manufacturing and convenience advantages; NDA submission is complete and approval is likely. I maintain a Buy rating on URGN stock, citing robust early commercial execution, significant market penetration potential, and ongoing pipeline progress, despite a short cash runway and execution risks. Read the full article on Seeking Alpha
Aggiornamento narrativa • Aug 27
URGN: Future Profit Margins Will Improve Through Bladder Cancer Pipeline Momentum
Analysts have raised the blended fair value estimate for UroGen Pharma to about $60 per share, citing expectations for higher profit margins and increased confidence in Zusduri product sales, as reflected in recent price target increases from firms including TD Cowen, Guggenheim, Oppenheimer, and Goldman Sachs. Analyst Commentary Recent research updates on UroGen Pharma focus heavily on Zusduri execution, sales trajectories, and how these flow through to valuation.
Aggiornamento narrativa • Aug 13
URGN: Future Bladder Cancer Franchise Durability May Reframe Long Term Upside Potential
Analysts have raised their fair value estimate for UroGen Pharma from $45.0 to $75.0, citing higher product sales expectations and stronger projected revenue growth, profit margins, and future P/E metrics. These revisions are supported by recent upward adjustments to Zusduri sales forecasts and price targets across several research firms.Articolo di analisi • Aug 07
Bullish: Analysts Just Made An Incredible Upgrade To Their UroGen Pharma Ltd. (NASDAQ:URGN) Forecasts
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders will have a reason to smile today, with the analysts making substantial...Aggiornamento narrativa • Jul 30
URGN: Patent Duration And Bladder Cancer Franchise Will Shape Balanced Upside Potential
Analysts have raised the fair value estimate for UroGen Pharma to $40.00 from $32.00, citing updated sales projections for Zusduri, favorable survey feedback from prescribing urologists, and expectations for longer patent protection that could limit generic competition in non muscle invasive bladder cancer. Analyst Commentary Recent research updates on UroGen Pharma point to a mix of optimism around Zusduri and ongoing caution about execution and long term growth.Aggiornamento narrativa • Jul 16
URGN: Extended Patent Optimism Will Likely Outrun Realistic Commercial Execution
For UroGen Pharma, the analyst price target in this framework shifts from $20.55 to $32.00 as analysts factor in extended patent protection on its gel-based mitomycin franchise and early Zusduri launch progress, along with updated assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research on UroGen Pharma highlights a mix of optimism around extended patent protection and Zusduri launch traction, alongside pockets of caution where some bearish analysts remain focused on execution risks, competition, and how much of the good news is already reflected in valuation.Aggiornamento narrativa • Jun 18
URGN: Patent Overhang And Execution Risks Will Likely Cap Stock Price Upside
Analysts have trimmed their average price target for UroGen Pharma to about $20.55, a slight adjustment they link to updated assumptions around revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent Street research around UroGen Pharma highlights a mix of optimism on the product story and tighter scrutiny on what that implies for valuation, especially relative to updated assumptions on revenue, margins and future P/E multiples.Aggiornamento narrativa • Jun 04
URGN: Future Bladder Cancer Trial Milestones May Reframe Long Term Upside Potential
Analysts have reset the 12 month price target for UroGen Pharma to $45.00, reflecting updated assumptions around revenue growth, profit margins, and a slightly higher discount rate, while citing supportive recent research coverage and target increases from multiple firms. Analyst Commentary Recent research coverage on UroGen Pharma has leaned positive, with several bullish analysts updating their views and models following new information on the company and its pipeline.Aggiornamento narrativa • May 21
URGN: Future Regulatory And Funding Setbacks Will Likely Restrain Upside Potential
Narrative Update on UroGen Pharma The updated analyst price target for UroGen Pharma has shifted from about $19.68 to roughly $20.86 as analysts incorporate recent initiations and target increases, including the $5 and $6 target hikes and renewed Buy views, into their valuation work. Analyst Commentary Recent research on UroGen Pharma has leaned constructive, with several firms initiating or reaffirming Buy views and lifting their price targets.Aggiornamento narrativa • May 03
URGN: Future Regulatory And Cost Setbacks Will Likely Restrain Upside Potential
Analysts have raised their price target on UroGen Pharma from $16.57 to $19.68 as updated assumptions for revenue growth, profit margins and a lower future P/E multiple align with a recently initiated bullish view on the stock. Analyst Commentary Recent research commentary on UroGen Pharma reflects a bullish initiation that aligns with the higher price target.Aggiornamento narrativa • Apr 18
URGN: Future Profit Margins Will Improve Through LG UTUC Trial Momentum
Analysts have nudged their price target for UroGen Pharma higher to $36.11 from $35.63, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E following recent bullish Street research coverage. Analyst Commentary Recent Street research on UroGen Pharma has leaned constructive, which feeds into the modest uptick in the blended price target to $36.11.Aggiornamento narrativa • Apr 03
URGN: Future Profit Margins Will Improve Through New J Code Reimbursement
Analysts have modestly fine-tuned their price target framework for UroGen Pharma, keeping fair value around $35.63. Small adjustments to the discount rate, revenue growth, profit margin, and forward P/E reflect updated assumptions rather than a major change in outlook.Aggiornamento narrativa • Mar 20
URGN: Future Profit Margins Will Benefit From New J Code And Loan Refinancing
Analysts kept their fair value estimate for UroGen Pharma steady at $35.63 while making only minimal adjustments to assumptions around discount rate, revenue growth, profit margin, and future P/E. These changes reflect updated views on operating costs and financing conditions, similar to those that recently led to modest target reductions in other healthcare names.Aggiornamento narrativa • Mar 05
URGN: Future Profit Margins Will Benefit From New J Code Reimbursement
Analysts now place UroGen Pharma's fair value at about $35.63, compared with the prior $35.25. This reflects updated assumptions around a slightly higher discount rate, modestly adjusted revenue growth and profit margin expectations, and a higher future P/E estimate.Articolo di analisi • Dec 05
UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders have had their patience rewarded with a 26% share price jump in the...Aggiornamento narrativa • Nov 26
URGN: Future Profit Margins Will Benefit From Recent Regulatory Milestones
Analysts have raised their price target for UroGen Pharma from $33.75 to $35.25. They cite expectations of stronger revenue growth and improved profit margins as key drivers for the increase.Articolo di analisi • Oct 06
UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues
It's not a stretch to say that UroGen Pharma Ltd.'s ( NASDAQ:URGN ) price-to-sales (or "P/S") ratio of 8.5x right now...Aggiornamento narrativa • Sep 09
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
Driven by an improved net profit margin and a modest reduction in future P/E, analysts have raised UroGen Pharma’s consensus price target from $32.00 to $33.75. What's in the News ZUSDURI (mitomycin) received FDA approval as the first and only approved therapy for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with U.S. availability expected on or around July 1, 2025.Aggiornamento narrativa • Aug 15
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
As there is no change in the key metrics—consensus price target ($31.43), discount rate (6.85%), and future P/E (15.67x)—analyst valuation for UroGen Pharma remains steady, reflecting an unchanged fair value. What's in the News ZUSDURI (mitomycin) received FDA approval as the first and only medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with U.S. availability expected on or around July 1, 2025.Articolo di analisi • Aug 10
The UroGen Pharma Ltd. (NASDAQ:URGN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
NasdaqGM:URGN 1 Year Share Price vs Fair Value Explore UroGen Pharma's Fair Values from the Community and select yours...Articolo di analisi • Jul 07
Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders would be excited to see that the share price has had a great month...Articolo di analisi • May 17
Lacklustre Performance Is Driving UroGen Pharma Ltd.'s (NASDAQ:URGN) 30% Price Drop
The UroGen Pharma Ltd. ( NASDAQ:URGN ) share price has fared very poorly over the last month, falling by a substantial...Articolo di analisi • May 15
Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63
It's shaping up to be a tough period for UroGen Pharma Ltd. ( NASDAQ:URGN ), which a week ago released some...Nuova narrativa • May 07
UGN-102 Approval Will Broaden Bladder Cancer Treatment Options
Anticipated approval of UGN-102 could significantly expand UroGen Pharma's market, boosting revenues with its compelling response rates and potential pricing power.Articolo di analisi • Feb 12
Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet
You may think that with a price-to-sales (or "P/S") ratio of 4.8x UroGen Pharma Ltd. ( NASDAQ:URGN ) is definitely a...Seeking Alpha • Jan 31
UroGen: Upcoming PDUFA, Some Concerns Remain
Summary UroGen's Jelmyto, a gel-based mitomycin product for LG-UTUC, achieved $25.2mn in Q3 2024, marking a 20% YoY increase. Lead candidate UGN-102 shows promise in treating low-grade intermediate risk NMIBC, with significant clinical trial success and a PDUFA date set for June 13, 2025. Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva. Despite promising data and market potential, UroGen's low market cap suggests caution; a pilot investment is recommended with awareness of associated risks. Read the full article on Seeking AlphaArticolo di analisi • Nov 18
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Aug 28
UroGen Pharma: There Is Some Potential Here
Summary UroGen Pharma Ltd. focuses on urothelial and specialty cancers, with Jelmyto approved for LG-UTUC and promising pipeline candidates like UGN-102 for bladder cancer. UGN-102 should garner FDA approval in the first half of 2025 and has a much bigger potential market than Jelmyto. UroGen is also advancing some next-generation candidates within its pipeline and has adequate near-term funding in place. An analysis around UroGen Pharma follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jun 17
UroGen: Q3 NDA Opens Hefty Revenue Opportunity
Summary ENVISION DOR data released in Q2, 2024 showed an unprecedented 82.3% Duration of Response for UGN-102. Following such positive data, it expects to make an FDA submission late in Q3, 2024, with potential for priority review. UroGen Pharma's blockbuster drug potential, liquidity, and modest market cap make it a strong buy. Read the full article on Seeking AlphaArticolo di analisi • Jun 14
UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders would be excited to see that the share price has had a great month...Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di URGN siano rimasti stabili in passato.
Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di URGN siano aumentati.
Rendimento dei dividendi rispetto al mercato
| UroGen Pharma Rendimento dei dividendi rispetto al mercato |
|---|
| Segmento | Rendimento dei dividendi |
|---|---|
| Azienda (URGN) | n/a |
| Fondo del 25% del mercato (US) | 1.4% |
| Top 25% del mercato (US) | 4.1% |
| Media del settore (Biotechs) | 2.2% |
| Analista previsionale (URGN) (fino a 3 anni) | 0% |
Dividendo notevole: Impossibile valutare il rendimento dei dividendi di URGN rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Dividendo elevato: Impossibile valutare il rendimento dei dividendi di URGN rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Distribuzione degli utili agli azionisti
Copertura degli utili: Dati insufficienti per calcolare il payout ratio di URGN per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché URGN non ha segnalato alcun pagamento.
Scoprire le società che pagano dividendi forti
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/11 04:31 |
| Prezzo dell'azione a fine giornata | 2026/09/11 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
UroGen Pharma Ltd. è coperta da 21 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Anita Dushyanth | Berenberg |
| Paul Choi | Goldman Sachs |
| Kelsey Goodwin | Guggenheim Securities, LLC |